Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.

Front Immunol · 2025 · PMC12464006 · PMID 41019062

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, other potentially explanatory variables, such as age and pre-ICI IL-6 levels, did not reach statistical significance in our analysis ( Table 3 ).

also in 111,027 other papers

showed a trendno p-value reported

In contrast, women and patients with pre-existing immune-mediated diseases showed a trend towards lower pre-ICI IL-6 levels ( Supplementary Table S1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.